PTP1B negatively regulates nitric oxide-mediated Pseudomonas aeruginosa killing by neutrophils
Authors:
Lei Yue aff001; Min Yan aff002; Michel L. Tremblay aff003; Tong-Jun Lin aff004; Hua Li aff001; Ting Yang aff001; Xia Song aff001; Tianhong Xie aff001; Zhongping Xie aff001
Authors place of work:
The Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, Yunnan, China
aff001; Department of Microbiology and Immunology, Kunming Medical University, Kunming, Yunnan, China
aff002; Rosalind and Morris Goodman Cancer Research Centre, Department of Biochemistry, McGill University, Montréal, Quebec, Canada
aff003; Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada
aff004; Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada
aff005
Published in the journal:
PLoS ONE 14(9)
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0222753
Summary
Neutrophils play a critical role in host defense against Pseudomonas aeruginosa infection. Mechanisms underlying the negative regulation of neutrophil function in bacterial clearance remain incompletely defined. Here, we demonstrate that protein tyrosine phosphatase-1B (PTP1B) is a negative regulator of P. aeruginosa clearance by neutrophils. PTP1B-deficient neutrophils display greatly enhanced bacterial phagocytosis and killing, which are accompanied by increased Toll-like receptor 4 (TLR4) signaling activation and nitric oxide (NO) production following P. aeruginosa infection. Interestingly, PTP1B deficiency mainly upregulates the production of IL-6 and IFN-β, leads to enhanced TLR4-dependent STAT1 activation and iNOS expression by neutrophils following P. aeruginosa infection. Further studies reveal that PTP1B and STAT1 are physically associated. These findings demonstrate a negative regulatory mechanism in neutrophil underlying the elimination of P. aeruginosa infection though a PTP1B-STAT1 interaction.
Keywords:
Biology and life sciences – Cell biology – Biochemistry – Organisms – Research and analysis methods – Cell processes – Molecular biology – Neuroscience – Molecular biology techniques – Developmental biology – Cellular types – Animal cells – Medicine and health sciences – Microbiology – Medical microbiology – Microbial pathogens – Bacterial pathogens – Pseudomonas aeruginosa – Bacteria – Pseudomonas – Pathology and laboratory medicine – Pathogens – Physiology – immunology – immune system – Innate immune system – Cytokines – Immune physiology – Molecular development – Blood cells – White blood cells – immune cells – Artificial gene amplification and extension – Polymerase chain reaction – Neurochemistry – Neurochemicals – signal transduction – Cell signaling – Nitric oxide – Neutrophils – Phagocytosis – Membrane receptor signaling – Immune receptor signaling – STAT signaling
Introduction
Pseudomonas aeruginosa is a prevalent opportunistic pathogen that is the common cause of exacerbations of chronic obstructive pulmonary disease (COPD)[1] and community acquired pneumonia (CAP)[2]. It is also the predominant pathogen-based cause of morbidity and mortality in cystic fibrosis (CF) patients[3, 4]. The innate immune response plays a critical role in host defense against P. aeruginosa infection[5]. This immune process requires the effective production of cytokines and chemokines to recruit neutrophils to inflammatory sites, which culminates in the phagocytosis and killing of the bacterium[6, 7]. A key factor for controlling P. aeruginosa is the maintenance of a balanced immune response, which effectively eliminates P. aeruginosa without causing detrimental inflammation and tissue damage[8, 9]. However, the mechanisms remain incompletely defined.
Neutrophils are an important line of host defense to combat P. aeruginosa pulmonary infection[10]. Neutrophils express all tested TLRs except TLR3, which are activated by bacterial pathogen-associated molecular patterns (PAMPs) and can induce downstream signaling pathways[11] that lead to the formation of phagosomes and lysosomes that kill bacteria. The oxidative attack on phagocytosed microbes, that occurs in neutrophils, employs highly toxic reactive oxygen species (ROS) and reactive nitrogen species (RNS), which damage intracellular components and kill extracellular pathogens[12]. P. aeruginosa has also evolved strategies to impair the bactericidal function of ROS[13]. Nitric oxide (NO), as the major effector of RNS, can eliminate bacteria, especially P. aeruginosa resistant to ROS[14].
NO production relies on transcriptional activation of the inducible nitric oxide synthase (iNOS) gene. The expression of iNOS is activated by pathogens binding to TLRs and requires the participation of multiple downstream cytokines and transcription factors[15, 16]. The synthesis of NO in neutrophils is regulated by tightly controlled epigenetic modifications, in which phosphorylation and dephosphorylation are fundamental mechanisms of expression regulation[17]. The coordinated actions of protein tyrosine kinases and protein tyrosine phosphatases determine the level of tyrosine phosphorylation in a reversible manner[18].
PTP1B belongs to the protein tyrosine phosphatase family, and its activity is sensitive to a wide variety of extracellular stimuli, such as insulin, growth factor signaling and amino acid starvation[19]. Roles for PTP1B in inflammation and innate immunity have also been demonstrated. Xu et al. reported a negative regulatory role for PTP1B in response to various TLR ligands which through inhibition of MyD88, TRIF, IRF3 and STAT1 dependent pathways[20]. Regulatory role for PTP1B has been proposed in the STATs signaling pathway. PTP1B has been shown to dephosphorylated the JAK2 and Tyk2[21], as well as STAT3[22], exerting a negative effect on activation of the pathway.
We have demonstrated the pivotal role of protein tyrosine phosphatase-1B (PTP1B) in resisting P. aeruginosa lung infection [23]. Our findings showed that in PTP1B-deficient mice, the clearance of P. aeruginosa was significantly enhanced due to neutrophil recruitment. However, whether PTP1B is important in direct killing of P. aeruginosa by neutrophils have not been reported previously.
In this study, we employed an in vitro neutrophil model to demonstrate that PTP1B negatively regulates the phagocytosis and NO-dependent killing of P. aeruginosa. This process is mediated by the TLR4-STAT1-iNOS signaling pathway. Importantly, we revealed that STAT1 is the target of PTP1B regulation. Hence, our study illustrates the key activities of PTP1B in neutrophil resistance to P. aeruginosa infection.
Materials and methods
Animals
PTP1B-deficient mice (C57BL/6 background) were originally provided by Michel L. Tremblay (McGill Cancer Centre, Montréal, QC, Canada). Animal care and experimental protocols were reviewed and approved by the Yunnan Provincial Experimental Animal Management Association and the Experimental Animal Ethics Committee of the Institute of Medical Biology, Chinese Academy of Medical Sciences, according to the national guidelines on animal work in China. The animals were housed in specific pathogen free facilities and anesthetized with ketamine to minimize pain during relevant procedures.
Antibodies
Antibodies against hPTP1B (sc-133259) and actin (sc-1616) as well as rabbit anti-goat IgG HRP (sc-2768), goat anti-rabbit IgG HRP (sc-2004) and goat anti-mouse IgG-HRP (sc-2004) antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX). Antibodies against phospho-STAT1 (#7649), STAT1 (#9172), iNOS (#13120), hSTAT1 (#14994), hSTAT1 (#9176) and hPTP1B (#5311) were purchased from Cell Signaling Technology (Danvers, MA). An anti-Flag antibody was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).
Bacterial preparation
P. aeruginosa strain 8821 was cultured in Luria-Bertani broth at 37°C and harvested when the culture reached an optical density (OD) at 600 nm of 2.5–3 OD units (early stationary phase). Bacteria were washed in phosphate buffer and resuspended in PBS for in vitro assays. The P. aeruginosa strain 8821 (a gift from A. Chakrabarty, University of Illinois, Chicago, IL) used in cell culture assays was killed using an antibiotic mixture (50 U/ml penicillin, 50 U/ml streptomycin, 100 μg/ml piperacillin, 100 μg/ml ceftazidime, and 200 μg/ml gentamycin).
Phagocytosis assay
Bone marrow-derived neutrophils were isolated from mice following the protocol of the Mouse Neutrophil Negative Selection Kit (STEMCELL Technologies Inc.). P. aeruginosa 8821 was opsonized with 10% mouse serum for 30 min at 37°C. The neutrophils were counted and then incubated with preopsonized P. aeruginosa 8821 (multiplicity of infection (MOI) = 10) at 37°C for 30 min. The neutrophil pellet was washed with PBS and then treated with PBS containing 0.1% trypsin and 0.02% EDTA for 15 min at room temperature. Neutrophils were resuspended in PBS containing 10% mouse serum. Specimens were prepared using the Cytospin™ 4 Cytocentrifuge (Thermo Fisher Scientific, Waltham, MA). The centrifuged specimens were then stained with a Diff-Quik™ staining set (Siemens Healthcare Diagnostics Inc., Newark, DE) and examined under oil immersion. The number of bacteria engulfed by 100 randomly selected neutrophils was counted. The phagocytic activity was measured according to the rate of phagocytosis and the phagocytosis index. The rate of phagocytosis = number of cells containing bacteria/number of cells counted) X 100%. The phagocytosis index = total number of bacteria in all cells/ number of cells counted.
Intracellular bacterial killing assay
Neutrophils were isolated as described above and incubated with P. aeruginosa 8821 (opsonized with mouse serum) at 37°C for 1 h. Gentamycin was added at a final concentration of 200 mg/ml for 3 h to kill extracellular bacteria. Then, the neutrophils were washed with PBS and lysed with PBS containing 0.1% Triton X-100. The samples were serially diluted and spread onto Luria broth (LB) agar plates. Colony numbers were determined after an overnight incubation at 37°C.
Measurement of NO production
Neutrophils were left untreated (NT) or pretreated with TLR4-antagonist (InvivoGen, Catalog#: tlrl-prslps, 10 μg/mL) for 1 h. Then they were left untreated (NT) or exposed to P. aeruginosa 8821. Cell-free supernatants were collected and analyzed for NO production following the protocol of the Griess Reagent System Kit (Promega, Madison, WI).
Cytokine production
The concentrations of IL-1β, TNF, IL-6, IFNβ, IP10 and RANTES in culture supernatants were determined by enzyme-linked immunosorbent assay (ELISA) as described previously[24] using DuoSet® Ab pairs from R&D Systems (Minneapolis, MN). Briefly (e.g. IL-6 ELISA), 96-well plates were coated with an anti-mouse IL-6 antibody for 16–20 h at 4 °C. Nonspecific binding to the plates was blocked using a 1% bovine serum albumin solution in PBS for 1 h at room temperature. A total of 50 μL/well IL-6 standard and samples were added to the plate and incubated for 18–20 h at 4 °C. A biotinylated anti-murine IL-6 antibody was added to each well and incubated for 1 h at room temperature. Streptavidin-HRP (100 μL/well) was added for 30 min at room temperature according to the manufacturer’s instructions. 100 μL/well of 1X TMB Solution was added to each well, and the reaction was stopped with 100 μL Stop Solution (0.5 M H2SO4). The plate was read at 450 nm and the data was analyzed.
RNA isolation and qPCR
Total RNA was isolated from neutrophils using TRIzol (Thermo Fisher Scientific) and the RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was reverse transcribed by using the GoScript™ Reverse Transcription System (Promega, Madison, USA). Real-time quantitative PCR was performed with the Bio-Rad CFX-96 Real-Time System. Primer sequences are listed in S1 Table.
RT2 profiling assay
Real-time PCR profiling of mRNAs was conducted with the SYBR Green-based RT2 Profiler PCR Array System (Qiagen). Briefly, total RNA was extracted, and first-strand cDNA was synthesized using the RT2 First Strand Kit (Qiagen). A PCR primer assay was performed using SYBR Green Supermix (Qiagen) and gene-specific primers that attached to the bottom of the mouse phagocytosis array panel in the CFX96 Real-Time PCR Detection System (Bio-Rad). PCR primer assay data were analyzed on the Qiagen analysis website (www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/), and the scatter plot result was the output.
Immunoblotting
Cells samples were lysed with RIPA buffer and quantified by using the BCA Protein Assay Kit (Thermo Fisher Scientific). Cell lysates (25 μg) were subjected to electrophoresis on 10% SDS polyacrylamide gels. The proteins were transferred to polyvinylidene difluoride membranes, blotted with primary and secondary antibodies as indicated, and detected by an ECL detection system (SuperSignal™ West Pico PLUS Chemiluminescent Substrate, Thermo Fisher Scientific). Scanning densitometry was performed using Scion Image (Scion, Frederick, MD).
Co-Immunoprecipitation
Co-immunoprecipitation was performed using Protein A/G-agarose beads and then mixed with the relevant antibody. The target proteins were detected using immunoblotting as above.
Statistics
The data are presented as the means ± SEM of the indicated number of experiments. Statistical significance between multiple treatments was determined by one-way analysis of variance and Tukey’s post hoc honest significance test. Alternatively, when two independent variables were analyzed, two-way analysis of variance and Bonferroni’s multiple-comparison test were used. Statistical analysis was performed using GraphPad Prism software version 5.04 (GraphPad Software Inc., La Jolla, CA). Differences were considered significant at *p < 0.05, **p < 0.01, and ***p <0.001.
Results
1. PTP1B negatively regulates the phagocytosis of P. aeruginosa by neutrophils
To examine whether PTP1B affects the phagocytosis of P. aeruginosa, bone marrow-derived neutrophils from wild-type or PTP1B-deficient mice were infected with P. aeruginosa strain 8821. The infected cells were observed under a microscope after Diff-Quik™ staining, and the phagocytosis rate (Fig 1A, S1 Fig) and phagocytosis index (Fig 1B) were assessed. The results showed that the phagocytosis ability of PTP1B-deficient neutrophils was significantly increased.
To investigate the effects underlying the negative regulation of PTP1B in phagocytosis, qPCR array assays were performed with the P. aeruginosa-infected wild-type or PTP1B-deficient neutrophils. The mRNA levels of Fc-gamma receptors (Fcgr1), myeloid differentiation primary response 88 (Myd88) and colony stimulating factor 2 (Csf2) were increased in the PTP1B-deficient neutrophils (Fig 1C). The increased Fcgr1 expression was also confirmed by qPCR (S2A Fig). Then, we used STRING (string-db.org) to predict the functions of the three proteins. In addition to functioning in phagocytosis, Fcgr1, Myd88 and Csf2 may activate TLR4-related signaling (Fig 1D). QPCR also showed that in the PTP1B-deficient neutrophils, the level of TLR4, which is the major innate immune receptor activated by P. aeruginosa, exhibited a rising trend (S2B Fig). These findings revealed that PTP1B negatively regulates the phagocytosis of P. aeruginosa by neutrophils.
2. Negative regulation of PTP1B on P. aeruginosa killing by neutrophils
Neutrophils stand at the forefront of innate immunity through their capacities to engulf and kill P. aeruginosa. Because PTP1B has a negative regulatory effect on phagocytosis, we next examined whether PTP1B affects the killing of P. aeruginosa by neutrophils. PTP1B-deficient and wild-type neutrophils were infected with P. aeruginosa strain 8821. Bacterial burden was assessed by CFU counting. Significantly fewer bacteria were detected in the PTP1B-deficient neutrophils compared with that of wild-type neutrophil (Fig 2), suggesting that PTP1B-deficient neutrophils are more efficient in clearing P. aeruginosa.
3. Negative regulation of PTP1B on NO production by neutrophils following P. aeruginosa infection
Notably, the cytokines downstream of TLR4-related signaling, such as IL-6 and IFN-β, can induce NO production to facilitate bacterial killing[25]. We found that the expression of both IL-6 and IFN-β increased significantly in the PTP1B-deficient neutrophils (Fig 3A–3D). PTP1B deficiency has no effect on the production of IP10, RANTES, TNF and IL-1β by neutrophil following P. aeruginosa infection (S3 Fig). Subsequently, we analyzed NO production in the PTP1B-deficient neutrophils upon P. aeruginosa challenge and showed that it was negatively regulated by PTP1B in a TLR4-dependent manner (Fig 3E).
4. PTP1B activates TLR4-STAT1-iNOS signaling
Cytokine-activated NO production involves a variety of components. It is unclear whether these molecules are regulated by PTP1B. To address this question, qPCR arrays were used to assess the NO pathway. The results revealed that only the iNOS (NOS2) mRNA levels significantly increased (Fig 4A), which was corroborated by protein abundance analysis using Western blotting (Fig 4B). INOS, whose expression is modulated by the upstream transcription factor STAT1, induces NO production[26]. The data revealed that STAT1 phosphorylation and expression levels were both negatively regulated by PTP1B (Fig 4B). And the PTP1B regulated expression of STAT1 and iNOS could be blocked by TLR4 antagonist (Fig 4C and 4D). Our findings indicated that the TLR4-STAT1-iNOS axis is the main signaling pathway negatively regulated by PTP1B in NO-mediated bacterial killing.
5. STAT1 is the target of PTP1B
STAT1 is activated by tyrosine phosphorylation, and whether it is the target of PTP1B has not been reported previously. In this study, the interaction between PTP1B and STAT1 was verified by an immunoprecipitation assay. Specifically, PTP1B and STAT1 were expressed in HEK293 cells. Pulling down either PTP1B or STAT1 demonstrated that the two proteins interacted with each other (Fig 5A and 5B), which was relieved after P. aeruginosa infection (S4 Fig). Together, these results demonstrated that the targeting of STAT1 by PTP1B facilitates the PTP1B-mediated negative regulation of the neutrophil killing of P. aeruginosa by the TLR4-STAT1-iNOS pathway.
Discussion
P. aeruginosa causes pulmonary infection in immune-compromised individuals and leads to tissue damage or a decline in lung function[27]. Hence, a calculated innate immune response is essential for eliminating P. aeruginosa infection. Protein tyrosine phosphatase plays an important role in the host immune response against pathogen infection by regulating phosphorylation[28]. We previously reported that PTP1B negatively regulates P. aeruginosa lung infection through the interferon I pathway[23]. Neutrophil infiltration in lungs of PTP1B-deficient mice significantly increased, which may contribute to effective pulmonary bacterial clearance[23]. However, the mechanism remained incompletely understood. This study revealed that PTP1B targets STAT1 and regulates the NO-mediated clearance of P. aeruginosa by neutrophils. Our results not only showed that PTP1B is responsible for the negative regulation of the TLR4-STAT1-iNOS signaling pathway but also demonstrated the interaction between PTP1B and STAT1.
Neutrophils are the first line of defense against bacterial infection. During the mobilization of the immune system, neutrophils take the lead to reach the inflammatory site of P. aeruginosa infection and kill the bacteria. As such, they constitute a pivotal component of the acute inflammatory response[29]. Neutrophils express a variety of receptors. By opsonization, Fcgr1 mediates the phagocytosis of bacterial-antibody complexes by neutrophils. Our study revealed that phagocytosis was enhanced in PTP1B-deficinet neutrophils and the expression of Fcgr1 was increased. In addition, P. aeruginosa activated the innate immune signaling pathway through TLRs and increased the expression level of bactericidal components. This study focused on the RNS pathway. NO, as an important effector of the RNS pathway, is one of the most important compounds produced by neutrophils for eliminating bacteria. In the immune system, the activation of neutrophils results in the generation of iNOS, which catalyzes L-arginine to produce NO. In addition, the TLR signaling pathway activates iNOS production through multiple transcription factors[30]. The regulatory mechanisms of this process remain unclear. We provide strong evidence showing that PTP1B is a key regulator.
We previously reported that macrophages[31], mast cells[32] and dendritic cells[23] play crucial roles in P. aeruginosa infection. Recently, our study revealed that platelet-binding neutrophils were involved in the clearance of P. aeruginosa in the lungs[24]. These studies suggest that different immune cells play distinct roles in host defense against P. aeruginosa infection. We have demonstrated that the regulation of PTP1B in P. aeruginosa-infected mice is mainly concentrated on the TRIF-IRF-IFN signaling pathway and that a similar trend is also observed in dendritic cells in vitro[23]. In this study, we found that IL-6 and IFN-β were negatively regulated by PTP1B. These results not only indicated that PTP1B can selectively modulate the expression of some downstream cytokines in neutrophils, but also suggested that the downstream signals activating these two cytokines may contribute to the neutrophil-mediated elimination of P. aeruginosa.
JAK/STAT signaling is usually stimulated by cytokines, such as IL-6, IFN-β, and TNF. It is widely involved in various immunopathological processes, including cancer development and pathogen infection[33]. STAT1[34], STAT3[35] and STAT6[36] are important components of immune responses and inflammation. We previous demonstrated the unique role of STAT4 in innate immunity in P. aeruginosa infection[37]. PTP1B is an important molecule in modulating the JAK/STAT signaling pathway. In PTP1B-deficient mice, the dysregulation of the JAK/STAT signaling pathway is the main cause of some immune dysfunction[38]. STAT3[39] and STAT6[40] are the substrates of PTP1B. STAT1 is a major connection between the two canonical TLRs and the JAK/STAT pathways[41], but its role in antibacterial immunity has not been well understood. In addition, although STAT1 can also be activated by tyrosine phosphorylation, whether it is the target of PTP1B has not been reported. Herein, we report for the first time that STAT1, as the target of PTP1B, is involved in bacterial clearance. This finding reminds the important roles of STATs in counteracting pathogen infection[42].
Considering the role of PTP1B in the neutrophil-mediated elimination of P. aeruginosa, PTP1B inhibitors have therapeutic potential[43]. Although the properties of PTP1B have made it difficult to investigate this protein, in recent years a number of breakthrough achievements have been accomplished in the research and development of PTP1B inhibitors[44]. Meanwhile, we will monitor the efficacy of these inhibitors in clinical application.
Supporting information
S1 Fig [a]
PTP1B deficiency enhances the phagocytosis of . by neutrophils and has no effect on cell number and purity.
S2 Fig [nt]
PTP1B-deficient neutrophils display activated and transcription following . infection.
S3 Fig [nt]
PTP1B deficiency has no effect on the production of IP10, RANTES, TNF, and IL-1β by neutrophil following . infection.
S4 Fig [a]
The interaction of STAT1 and PTP1B is relieved after . infection.
S1 Table [docx]
Primers for qPCR.
Zdroje
1. Choi J, Oh JY, Lee YS, Hur GY, Lee SY, Shim JJ, et al. Pseudomonas aeruginosa infection increases the readmission rate of COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:3077–83. doi: 10.2147/COPD.S173759 30323578
2. Cilloniz C, Gabarrus A, Ferrer M, Puig de la Bellacasa J, Rinaudo M, Mensa J, et al. Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant Pseudomonas aeruginosa. Chest. 2016;150(2):415–25. doi: 10.1016/j.chest.2016.03.042 27060725.
3. Cripps AW, Dunkley ML, Clancy RL, Kyd J. Pulmonary immunity to Pseudomonas aeruginosa. Immunol Cell Biol. 1995;73(5):418–24. doi: 10.1038/icb.1995.65 8595919.
4. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16(1):174. doi: 10.1186/s12890-016-0339-5 27919253
5. Lavoie EG, Wangdi T, Kazmierczak BI. Innate immune responses to Pseudomonas aeruginosa infection. Microbes Infect. 2011;13(14–15):1133–45. doi: 10.1016/j.micinf.2011.07.011 21839853
6. Cigana C, Lore NI, Riva C, De Fino I, Spagnuolo L, Sipione B, et al. Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections. Sci Rep. 2016;6:21465. doi: 10.1038/srep21465 26883959
7. Parker D, Ahn D, Cohen T, Prince A. Innate Immune Signaling Activated by MDR Bacteria in the Airway. Physiol Rev. 2016;96(1):19–53. doi: 10.1152/physrev.00009.2015 26582515
8. Berger M. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy. 1991;9(1–2):119–42. 1884321.
9. Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, Ferkol T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest. 1997;100(11):2810–5. doi: 10.1172/JCI119828 9389746
10. Koh AY, Priebe GP, Ray C, Van Rooijen N, Pier GB. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun. 2009;77(12):5300–10. doi: 10.1128/IAI.00501-09 19805527
11. Futosi K, Fodor S, Mocsai A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int Immunopharmacol. 2013;17(3):638–50. doi: 10.1016/j.intimp.2013.06.034 23994464
12. Manda-Handzlik A, Demkow U. Neutrophils: The Role of Oxidative and Nitrosative Stress in Health and Disease. Adv Exp Med Biol. 2015;857:51–60. doi: 10.1007/5584_2015_117 25904001.
13. Vareechon C, Zmina SE, Karmakar M, Pearlman E, Rietsch A. Pseudomonas aeruginosa Effector ExoS Inhibits ROS Production in Human Neutrophils. Cell Host Microbe. 2017;21(5):611–8 e5. doi: 10.1016/j.chom.2017.04.001 28494242
14. Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Doring G, Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J Cyst Fibros. 2013;12(6):817–20. doi: 10.1016/j.jcf.2013.01.008 23481089.
15. Lewis RS, Kolesnik TB, Kuang Z, D’Cruz AA, Blewitt ME, Masters SL, et al. TLR regulation of SPSB1 controls inducible nitric oxide synthase induction. J Immunol. 2011;187(7):3798–805. doi: 10.4049/jimmunol.1002993 21876038.
16. Ji DB, Xu B, Liu JT, Ran FX, Cui JR. beta-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog. 2011;50(12):945–60. doi: 10.1002/mc.20762 21400616.
17. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004;75(6):639–53. doi: 10.1016/j.lfs.2003.10.042 15172174.
18. Atherton-Fessler S, Hannig G, Piwnica-Worms H. Reversible tyrosine phosphorylation and cell cycle control. Semin Cell Biol. 1993;4(6):433–42. 8305682.
19. Bourdeau A, Dube N, Tremblay ML. Cytoplasmic protein tyrosine phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr Opin Cell Biol. 2005;17(2):203–9. doi: 10.1016/j.ceb.2005.02.001 15780598.
20. Xu H, An H, Hou J, Han C, Wang P, Yu Y, et al. Phosphatase PTP1B negatively regulates MyD88- and TRIF-dependent proinflammatory cytokine and type I interferon production in TLR-triggered macrophages. Mol Immunol. 2008;45(13):3545–52. doi: 10.1016/j.molimm.2008.05.006 18571728.
21. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem. 2001;276(51):47771–4. doi: 10.1074/jbc.C100583200 11694501.
22. Lund IK, Hansen JA, Andersen HS, Moller NP, Billestrup N. Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J Mol Endocrinol. 2005;34(2):339–51. doi: 10.1677/jme.1.01694 15821101.
23. Yue L, Xie Z, Li H, Pang Z, Junkins RD, Tremblay ML, et al. Protein Tyrosine Phosphatase-1B Negatively Impacts Host Defense against Pseudomonas aeruginosa Infection. Am J Pathol. 2016;186(5):1234–44. doi: 10.1016/j.ajpath.2016.01.005 27105736.
24. Yue L, Pang Z, Li H, Yang T, Guo L, Liu L, et al. CXCL4 contributes to host defense against acute Pseudomonas aeruginosa lung infection. PLoS One. 2018;13(10):e0205521. doi: 10.1371/journal.pone.0205521 30296305
25. Jin YH, Li ZT, Chen H, Jiang XQ, Zhang YY, Wu F. Effect of dexmedetomidine on kidney injury in sepsis rats through TLR4/MyD88/NF-kappaB/iNOS signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(11):5020–5. doi: 10.26355/eurrev_201906_18094 31210339.
26. Kim HY, Baik JE, Ahn KB, Seo HS, Yun CH, Han SH. Streptococcus gordonii induces nitric oxide production through its lipoproteins stimulating Toll-like receptor 2 in murine macrophages. Mol Immunol. 2017;82:75–83. doi: 10.1016/j.molimm.2016.12.016 28038357.
27. Ryu JC, Kim MJ, Kwon Y, Oh JH, Yoon SS, Shin SJ, et al. Neutrophil pyroptosis mediates pathology of P. aeruginosa lung infection in the absence of the NADPH oxidase NOX2. Mucosal Immunol. 2017;10(3):757–74. doi: 10.1038/mi.2016.73 27554297.
28. Mustelin T, Vang T, Bottini N. Protein tyrosine phosphatases and the immune response. Nat Rev Immunol. 2005;5(1):43–57. doi: 10.1038/nri1530 15630428.
29. Liang X, Gupta K, Quintero JR, Cernadas M, Kobzik L, Christou H, et al. Macrophage FABP4 is required for neutrophil recruitment and bacterial clearance in Pseudomonas aeruginosa pneumonia. FASEB J. 2019;33(3):3562–74. doi: 10.1096/fj.201802002R 30462529.
30. Kim YI, Park SW, Kang IJ, Shin MK, Lee MH. Activin suppresses LPS-induced Toll-like receptor, cytokine and inducible nitric oxide synthase expression in normal human melanocytes by inhibiting NF-kappaB and MAPK pathway activation. Int J Mol Med. 2015;36(4):1165–72. doi: 10.3892/ijmm.2015.2308 26259928.
31. Junkins RD, MacNeil AJ, Wu Z, McCormick C, Lin TJ. Regulator of calcineurin 1 suppresses inflammation during respiratory tract infections. J Immunol. 2013;190(10):5178–86. doi: 10.4049/jimmunol.1203196 23589609.
32. Junkins RD, Carrigan SO, Wu Z, Stadnyk AW, Cowley E, Issekutz T, et al. Mast cells protect against Pseudomonas aeruginosa-induced lung injury. Am J Pathol. 2014;184(8):2310–21. doi: 10.1016/j.ajpath.2014.05.009 25043620.
33. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–84. doi: 10.1038/ni.3691 28323260.
34. Heinonen KM, Bourdeau A, Doody KM, Tremblay ML. Protein tyrosine phosphatases PTP-1B and TC-PTP play nonredundant roles in macrophage development and IFN-gamma signaling. Proc Natl Acad Sci U S A. 2009;106(23):9368–72. doi: 10.1073/pnas.0812109106 19474293
35. Lesina M, Wormann SM, Neuhofer P, Song L, Algul H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Semin Immunol. 2014;26(1):80–7. doi: 10.1016/j.smim.2014.01.002 24572992.
36. Walford HH, Doherty TA. STAT6 and lung inflammation. JAKSTAT. 2013;2(4):e25301. doi: 10.4161/jkst.25301 24416647
37. O’Sullivan R, Carrigan SO, Marshall JS, Lin TJ. Signal transducer and activator of transcription 4 (STAT4), but not IL-12 contributes to Pseudomonas aeruginosa-induced lung inflammation in mice. Immunobiology. 2008;213(6):469–79. doi: 10.1016/j.imbio.2007.11.007 18514749.
38. Pike KA, Hutchins AP, Vinette V, Theberge JF, Sabbagh L, Tremblay ML, et al. Protein tyrosine phosphatase 1B is a regulator of the interleukin-10-induced transcriptional program in macrophages. Sci Signal. 2014;7(324):ra43. doi: 10.1126/scisignal.2005020 24803538.
39. Roger T, David J, Glauser MP, Calandra T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature. 2001;414(6866):920–4. doi: 10.1038/414920a 11780066.
40. van Heeckeren AM, Tscheikuna J, Walenga RW, Konstan MW, Davis PB, Erokwu B, et al. Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med. 2000;161(1):271–9. doi: 10.1164/ajrccm.161.1.9903019 10619831.
41. Luu K, Greenhill CJ, Majoros A, Decker T, Jenkins BJ, Mansell A. STAT1 plays a role in TLR signal transduction and inflammatory responses. Immunol Cell Biol. 2014;92(9):761–9. doi: 10.1038/icb.2014.51 25027037.
42. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49. doi: 10.1038/nri3581 24362405
43. Zhang S, Zhang ZY. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today. 2007;12(9–10):373–81. doi: 10.1016/j.drudis.2007.03.011 17467573.
44. Wiese J, Aldemir H, Schmaljohann R, Gulder TAM, Imhoff JF. Asperentin B, a New Inhibitor of the Protein Tyrosine Phosphatase 1B. Mar Drugs. 2017;15(6). doi: 10.3390/md15060191 28635658
Článok vyšiel v časopise
PLOS One
2019 Číslo 9
- Metamizol jako analgetikum první volby: kdy, pro koho, jak a proč?
- Nejasný stín na plicích – kazuistika
- Masturbační chování žen v ČR − dotazníková studie
- Těžké menstruační krvácení může značit poruchu krevní srážlivosti. Jaký management vyšetření a léčby je v takovém případě vhodný?
- Fixní kombinace paracetamol/kodein nabízí synergické analgetické účinky
Najčítanejšie v tomto čísle
- Graviola (Annona muricata) attenuates behavioural alterations and testicular oxidative stress induced by streptozotocin in diabetic rats
- CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer’s disease
- Comparison between Aptima Assays (Hologic) and the Allplex STI Essential Assay (Seegene) for the diagnosis of Sexually transmitted infections
- Assessment of glucose-6-phosphate dehydrogenase activity using CareStart G6PD rapid diagnostic test and associated genetic variants in Plasmodium vivax malaria endemic setting in Mauritania